Articles

RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia

Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Laboratory of Experimental Hematology, Antwerp University Hospital (UZA), University of Antwerp, Antwerp
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Laboratory of Molecular & Cellular Therapy of the Department of Physiology and Immunology, Free University Brussels (VUB), Brussels University Hospital, Brussels, Belgium
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent University Hospital, Ghent
Vol. 97 No. 10 (2012): October, 2012 https://doi.org/10.3324/haematol.2012.065581